AI shortens drug discovery to around 1 year in China, Insilico CEO says | Reuters

Insilico Medicine has reduced drug discovery timelines to 9-13 months by combining generative AI with China-based research operations, compared to 4.5 years using traditional methods. The company's strategy leverages China's lower costs, streamlined regulation, and automated lab infrastructure to compete on speed against Western pharma giants while maintaining partnerships with Eli Lilly, Takeda, and others.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.